IBS is classified under the Rome IV criteria as a "disorder of gut-brain interaction" (DGBI) — a deliberate reframing from previous language of "functional" disorder that implied the symptoms were psychosomatic or imaginary. The Rome IV designation acknowledges that IBS involves measurable abnormalities in gut motility, intestinal permeability, mucosal immune activation, visceral sensitivity, and microbiome composition — none of which require conscious stress or psychological distress to occur, though psychological factors clearly modulate symptom severity through the gut-brain axis.
The gut-brain axis is bidirectional: the enteric nervous system (ENS), with 500 million neurons — more than the spinal cord — communicates with the central nervous system via the vagus nerve, spinal afferents, and the HPA (hypothalamic-pituitary-adrenal) stress axis. In IBS, this bidirectional communication is dysregulated: visceral hypersensitivity (lowered pain threshold in the gut) means the colon registers normal amounts of gas or distension as painful, and central sensitization amplifies these signals. This is a neurological phenomenon, not a character trait.
| Subtype | Predominant Pattern | Prevalence | First-Line Treatments |
|---|---|---|---|
| IBS-D (diarrhea-predominant) | >25% loose/watery stools (Bristol 6–7); urgency; post-meal cramping | ~40% of IBS | Low-FODMAP; rifaximin (gut-selective antibiotic); loperamide (symptom control); bile acid sequestrants if post-cholecystectomy |
| IBS-C (constipation-predominant) | >25% hard stools (Bristol 1–2); straining; incomplete evacuation; bloating | ~35% of IBS | Low-FODMAP; soluble fiber (psyllium); linaclotide or plecanatide (GC-C agonists); lubiprostone (ClC-2 agonist); osmotic laxatives (PEG) |
| IBS-M (mixed) | Both diarrhea and constipation patterns alternating (>25% each) | ~20% of IBS | Low-FODMAP; peppermint oil (works across subtypes); identify trigger patterns; antispasmodics for pain |
| IBS-U (unclassified) | Meets Rome IV criteria but doesn't fit D/C/M pattern | ~5% of IBS | Symptomatic management; low-FODMAP trial; gut-directed hypnotherapy has evidence across all subtypes |
FODMAP elimination (phase 1, 2–6 weeks) followed by systematic reintroduction (phase 2) and personalization (phase 3) is the most evidence-supported dietary intervention for IBS. The landmark Gibson & Shepherd Monash University trials in the 2000s–2010s established the mechanism: FODMAPs (fructose, lactose, fructans in wheat/onion/garlic, galacto-oligosaccharides in legumes, and polyols in stone fruits/sweeteners) are osmotically active and rapidly fermented, producing luminal distension and gas that triggers hypersensitive IBS gut walls. Removal reduces this substrate.
Critical caveat: the low-FODMAP diet reduces diversity of beneficial gut bacteria (particularly Bifidobacteria) during the elimination phase. It is not intended as a permanent diet — the reintroduction phase identifies individual tolerance thresholds so most foods can be reintroduced in tolerated amounts. A dietitian experienced in low-FODMAP is strongly recommended; unsupervised elimination frequently becomes nutritionally inadequate and unnecessarily restrictive.
Peppermint oil's active compound, L-menthol, blocks calcium channels in smooth muscle cells of the gut wall, producing a spasmolytic effect that reduces cramping and urgency. Enteric-coated capsules (not regular peppermint oil) are required to prevent premature release in the stomach (which would cause heartburn) and deliver the drug to the small intestine and colon where IBS symptoms originate.
Alammar et al. 2019 meta-analysis (12 RCTs, N=835): peppermint oil significantly superior to placebo for global IBS symptoms (RR 2.39), abdominal pain (RR 1.78), and total symptom score. NNT 2.5 for global symptom relief — comparable to or better than many prescription antispasmodics with superior tolerability. The most common side effect is a temporary menthol sensation in the esophagus if taken without adequate water or if capsules are non-enteric-coated.
Rifaximin is a non-absorbed antibiotic that stays in the GI tract (minimal systemic absorption), altering small intestinal and colonic bacterial populations without systemic antibiotic side effects. The TARGET 1 and TARGET 2 trials (Pimentel et al. 2011, N=1,260 combined) showed rifaximin 550mg × 3/day for 14 days produced global IBS symptom relief in 57% vs 32% placebo (NNT ~4). The effect lasted 10–12 weeks post-treatment. Notably, this is the same antibiotic used for H2-SIBO (rifaximin 77% eradication) — supporting the hypothesis that at least some IBS-D is driven by small intestinal bacterial overgrowth.
Gut-directed hypnotherapy (GDH), developed by Peter Whorwell at the University of Manchester, uses hypnotic induction combined with imagery and suggestions focused specifically on gut function (rather than general relaxation). The Manchester protocol (12 weekly sessions) showed 80% of IBS patients demonstrated significant improvement — a response rate exceeding most pharmacological treatments. A Cochrane systematic review (Webb et al. 2007, N=346) confirmed hypnotherapy significantly superior to supportive therapy and medical management for abdominal pain and overall well-being. The mechanism involves normalization of visceral hypersensitivity via top-down cortical modulation of gut afferent signaling. Limitation: highly therapist-dependent; qualified GDH practitioners for IBS are scarce.
Step 1 — Rule out structural causes first: IBS is a diagnosis of exclusion. Celiac disease (serology), inflammatory bowel disease (IBD — calprotectin + colonoscopy if indicated), colon cancer screening (per age/family history), and thyroid function should be evaluated before IBS is assumed. Red flags (rectal bleeding, unintentional weight loss, nocturnal symptoms, family history of IBD/colorectal cancer, onset after 50) require investigation.
Step 2 — Identify your subtype: Track stool form (Bristol Stool Chart) for 2 weeks to identify whether you're IBS-D, IBS-C, or IBS-M. Treatment selection differs significantly by subtype.
Step 3 — Low-FODMAP trial (with dietitian): 2–4 week strict elimination phase, then systematic reintroduction. Use the Monash University FODMAP app for accurate food classification. Do not remain in elimination phase longer than 6 weeks.
Step 4 — Add peppermint oil (all subtypes) or subtype-specific Rx: Enteric-coated peppermint oil 0.2–0.4mL (IBgard or equivalent) 30–90 minutes before meals, up to 3×/day. For IBS-D: rifaximin trial via gastroenterologist. For IBS-C: psyllium 5–10g/day with water + linaclotide if inadequate response.
Step 5 — Gut-brain axis interventions: Cognitive behavioral therapy (CBT) for IBS and gut-directed hypnotherapy have evidence comparable to pharmacotherapy. Stress modulation via HRV training or mindfulness reduces symptom severity independent of stool changes — confirming the afferent dysregulation component.
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.